4.5亿！国投再押合成生物，入局弈柯莱！多项产品为全国首家！

Core Insights - National Investment Group's subsidiary, Guotou Juli, has completed a strategic investment of 450 million RMB in the synthetic biology company Yikolei Biotech, marking another significant investment in the biomanufacturing sector following a previous investment of 300 million RMB in Muen Biotech in 2024 [1][2]. Company Overview - Yikolei Biotech, established in 2015, has developed a comprehensive synthetic biology technology pathway and industrial production capabilities, focusing on enzyme-biosynthesis routes and intelligent cell design [3]. - The company has a diverse product matrix and has become a strategic partner for several industry giants, maintaining a leading position in biomedicine and green agriculture, with recent breakthroughs in the nutrition and health sector [5]. Product Innovations - Yikolei Biotech is the first company in China to receive approval for several functional food ingredients, including HMOs (human milk oligosaccharides), steviol glycosides, and sialic acid [5]. Industry Event - The 2025 Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on AI and biomanufacturing, green chemicals, new materials, future food, and agriculture [7]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan, emphasizing technology transfer, product scaling, and talent acquisition [7].